|
A controlled study of
2 doses of idebenone in the treatment of Alzheimer's disease.
Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM.
Institute of Psychology,
Johann Wolfgang Goethe University,
Frankfurt/Main,
Germany.
Neuropsychobiology 1997;36(2):73-82
ABSTRACT
Two doses of idebenone were studied in a
prospective, randomized, double-blind, placebo-controlled multicentre study in
patients suffering from dementia of the Alzheimer type (DAT) of mild to
moderate degree. Diagnosis was based on DSM-III-R (primary degenerative
dementia) and NINCDS-ADRDA criteria (probable Alzheimer's disease). A total of
300 patients were randomized to either placebo, idebenone 30 mg t.i.d. or 90
mg t.i.d. (n = 100, each) and treated for 6 months. The primary outcome
measure was the total score of the Alzheimer's Disease Assessment Scale (ADAS-Total)
at month 6. Secondary outcome measures were the ADAS cognitive (ADAS-Cog) and
noncognitive scores (ADAS-Noncog), the clinical global response
(CGI-Improvement), the MMSE, the Digit Symbol Substitution test (DSS) and
several scales for the assessment of daily activities (the self- and
observer-rating scales NAA and NAB of the Nuremberg Age Inventory NAI and
Greene's Assessment). Safety parameters were adverse events, vital signs, ECG
and clinical laboratory parameters. Clinical and psychometric evaluations were
performed at baseline, and after 1, 3 and 6 months of treatment. After month 6
idebenone 90 mg t.i.d. showed statistically significant improvement in the
primary efficacy variable ADAS-Total and in ADAS-Cog. An analysis of therapy
responders performed for 3 outcome measures (CGI-global improvement, ADAS-Cog,
ADAS-Noncog), selected to represent different domains of assessment, revealed
significant superiority of idebenone 90 mg t.i.d. with respect to placebo in
each of the 3 variables and in the concordance of responses across the 3
measures. Exploratory results for a subgroup of patients (ADAS-Total > or =
20) showed dose-related superiority of idebenone additionally on ADAS-Noncog
and the CGI-Improvement scale. Safety results were inconspicuous for all
assessments. The study results demonstrate the efficacy and safety of
idebenone in the treatment of DAT patients.
Idebenone
-
the ultimate anti-aging drug. (article)
Alzheimer's disease
Idebenone in the treatment of
Alzheimer's disease
Idebenone efficacy of idebenone in the
treatment of Alzheimer's disease
Idebenone Nerve Growth Factor synthesis
stimulators in Alzheimer's disease
Idebenone in the treatment of dementia of
the Alzheimer type
Idebenone cognitive enhancement therapy
for Alzheimer's disease
MELAS
Idebenone improves cerebral
mitochondrial oxidative metabolism in MELAS
Idebenone
in young patients with
mitochondrial
encephalomyopathy (MELAS)
Idebenone therapy in
Mitochondrial
encephalomyopathy (MELAS)
Idebenone
and
Mitochondrial
encephalomyopathy (MELAS)
Idebenone successful therapy with idebenone in
Mitochondrial encephalomyopathy (MELAS)
.
Cardiomyopathy
Idebenone improvement in mitochondrial
cardiomyopathy following treatment with idebenone
Idebenone effect
of idebenone on cardiomyopathy in Friedreich's ataxia
.
Leber
hereditary optic neuropathy (LHON)
Idebenone
does it shorten the time to visual recovery in Leber
hereditary optic neuropathy?
Idebenone
improvement in a patient with Leber's hereditary optic neuropathy
(LHON)
Misc.
Misc.
Idebenone
use in age-related cognitive disorders
Idebenone
protects hippocampal neurons against beta amyloid neurotoxicity
Idebenone
functions as a potent protective
hepatocyte antioxidant
Idebenone
neuroprotective effects of
idebenone can be attributed to its antioxidant ability
Idebenone
inhibition of brain mitochondrial
swelling
Idebenone
suppression of cold ischemia/reperfusion
injury of liver endothelium
Idebenone
ability to eliminate a nitroxide
radical in the rat
Idebenone
interaction with respiratory complexes of heart
mitochondria
Idebenone
effect on serotonin release and seroton receptors in rats
Idebenone
protects hepatic microsomes against damage in organ preservation solutions
Idebenone
protects against toxicity
induced by low density lipoprotein
Idebenone
protects against disorders due to cerebral hypoxia or
ischemia
Idebenone
protects against toxicity induced by low density
lipoprotein
Idebenone
attenuates neuronal degeneration induced by excitotoxins
Idebenone
augments long-term potentiation in
hippocampal slices in the guinea pig
Idebenone
effects on electroencephalograms of patients
with cerebrovascular disorders
Idebenone
effects on
respiratory activities of brain mitochondria
Idebenone
effects
on lipid peroxidation
in erythrocytes of stroke-prone, hypertensive rats
Idebenone
brain distribution and its effect on local cerebral
glucose utilization in rats
Idebenone
effects
on acetylcholine levels
in the brains of rats with cerebral ischemia
Idebenone
protective effect of idebenone against hypoxia in mice
Idebenone
improves learning and memory impairment induced in rats
Idebenone
effects
of idebenone on
neurological deficits in stroke-prone rats
Idebenone
effects
on memory induced impairment in rats
Idebenone
effects of idebenone on cerebral blood flow in rats with cerebral ischemia
Idebenone
inhibition
of brain mitochondrial swelling by idebenone
Idebenone
inhibition of platelet aggregation by
idebenone
Idebenone
effects of idebenone on monoamine metabolites of patients
with dementia
Idebenone
effects of idebenone on
metabolism of monoamines and cyclic AMP formation
Idebenone effects
on impairment of radial maze learning in cerebral embolized rats
Idebenone
effect of idebenone on lipid peroxidation in rat
brain homogenate
Idebenone
effects on muricidal behavior in rats with raphe
lesions
Idebenone inhibitory effect of idebenone on vascular lesions in
hypertensive rats
Vinpocetine | Galantamine | CDP
Choline | Picamilon
Pyritinol | Modafinil | Deprenyl | Piracetam
Home | Order
|
